Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 10/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220526 | 0.91 | F10 (0.60) | F10LMNATSHRF2KLKB1 | |
| SCHEMBL221322 | 0.87 | F10 (0.66) | F10LMNATSHRF2 | |
| SCHEMBL222308 | 0.86 | F10 (0.65) | F10LMNATSHR | |
| SCHEMBL223513 | 0.85 | F10 (0.68) | F10LMNATSHR | |
| SCHEMBL220658 | 0.85 | F10 (0.63) | F10LMNATSHR | |
| SCHEMBL222580 | 0.84 | F10 (0.66) | F10LMNATSHRF2 | |
| SCHEMBL223191 | 0.83 | F10 (0.65) | F10LMNATSHRF2 | |
| SCHEMBL219591 | 0.82 | F10 (0.72) | F10LMNATSHRKMT2A | |
| SCHEMBL220513 | 0.82 | F10 (0.64) | F10LMNATSHRF2 | |
| SCHEMBL3878883 | 0.76 | HRH3 (0.37) | F10MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |